MedTrace Logo

A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials

NCT05827341 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2023-06-18

No results posted yet for this study

Summary

This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Guangzhou from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic,

Conditions

  • Malignant Lymphoma
  • Clinical Trial
  • COVID-19

Interventions

OTHER

No intervention

No intervention needed

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Zhiming Li · Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-01-31
Completion
2023-05-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05827341 on ClinicalTrials.gov